SCHEMBL15771663

SCHEMBL15771663

COC(=O)c1cccn1NC(=O)C(C)NC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
RCE1 Q9Y256 1/20 0.37
JAK2 O60674 2/20 0.37
SUV39H2 Q9H5I1 1/20 0.36
CTSS P25774 4/20 0.36
CTSK P43235 2/20 0.36
EPHX2 P34913 1/20 0.36
KMT2A Q03164 2/20 0.36
ATM Q13315 1/20 0.36
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
GLS O94925 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15771661 1.00 KDM4E (0.39) KDM4EALDH1A1HPGDRCE1JAK2
SCHEMBL1966568 0.84 NR1H2 (0.39) KDM4EALDH1A1KMT2ACTSLGAA
SCHEMBL13505420 0.83 MAPT (0.44) JAK2CTSSCTSKKMT2AATM
SCHEMBL13505424 0.83 MAPT (0.44) JAK2CTSSCTSKKMT2AATM
SCHEMBL15772515 0.82 NPC1 (0.41) KDM4EALDH1A1RCE1EPHX2KMT2A
SCHEMBL15772516 0.82 NPC1 (0.41) KDM4EALDH1A1RCE1EPHX2KMT2A
SCHEMBL15772589 0.81 CTSS (0.37) KDM4EJAK2CTSSCTSKKMT2A
SCHEMBL11037391 0.81 CNR2 (0.39) KDM4EALDH1A1HPGDRCE1SUV39H2
SCHEMBL15772590 0.81 CTSS (0.37) KDM4EJAK2CTSSCTSKKMT2A
SCHEMBL15771839 0.80 NPC1 (0.45) KDM4EALDH1A1RCE1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103649089-B Pyrrolotriazinones as PI3K inhibitors 阿尔米雷尔有限公司 2016-06-29 CN disclosed
US-9340547-B2 Pyrrolotriazinone derivatives as inhibitors P13K ALMIRALL, S.A. (ES) 2016-05-17 US disclosed
EP-2702061-B9 PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS ALMIRALL SA (ES) 2016-02-24 EP disclosed
EP-2702061-B1 PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS ALMIRALL SA (ES) 2015-07-29 EP disclosed
US-20150099752-A9 PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS ALMIRALL, SA (ES) 2015-04-09 US disclosed
US-20140163033-A1 PYRROLOTRIAZINONE DERIVATIVES AS P13K INHIBITORS ALMIRALL, SA (ES) 2014-06-12 US disclosed
CN-103649089-A Pyrrolotriazinones as PI3K inhibitors ALMIRALL SA 2014-03-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163033-A1 PYRROLOTRIAZINONE DERIVATIVES AS P13K INHIBITORS PIP4K2B, PDPK1, PI4KA KDM4E 1392/4885ALDH1A1 3142/4885HPGD 1914/4885
US-20150099752-A9 PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS PIK3CD, PIK3CA, PIK3CB KDM4E 2489/4885ALDH1A1 3538/4885HPGD 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.